alexa

GET THE APP

The Development Of Nonabsorbed Potassium Binding Polymer Microparticles (patiromer) For The Treatment Of Hyperkalemia | 53329
ISSN: 2155-6199

Journal of Bioremediation & Biodegradation
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

The development of nonabsorbed potassium binding polymer microparticles (patiromer) for the treatment of hyperkalemia

3rd International Conference and Exhibition on Biopolymers & Bioplastics

Bo Chen

Relypsa Inc., USA

ScientificTracks Abstracts: J Bioremed Biodeg

DOI: 10.4172/2155-6199.C1.002

Abstract
Hyperkalemia is a potentially life-threatening condition, and patients who have chronic kidney disease, who are diabetic, or who are taking renin-angiotensin-aldosterone system inhibitors are at increased risk. Therapeutic options for hyperkalemia tend to have limited effectiveness and can be associated with serious side effects. There are no new therapeutics for more than 50 years. Patiromer (USAN, trade name Veltassa) is a novel, spherical, nonabsorbed polymer designed to bind and remove potassium, primarily in the colon, thereby decreasing serum potassium in patients with hyperkalemia. The development process and the results of preclinical studies and early phase clinical study are reported here. Overall, patiromer is a high-capacity potassium binder and the chemical and physical characteristics of patiromer can lead to good clinical efficacy, tolerability and patient acceptance. It has been approved in 2015 by FDA used for the treatment of hyperkalemia.
Biography

Bo Chen is a Principal Scientist in Relypsa focusing on microparticles as toxin binders for various diseases. After his PhD in 2006 from New York University School of Engineering, and Post-doctoral studies from University of California San Francisco in 2009, he started his Sanofi-Genzyme career in Biomaterials and Drug Delivery Division. He left as a Senior Scientist in 2014 and joined biotech company CPGJ (Shanghai) as an Associate Director, later in GrayBug Inc. He has broad experience in Antibody Drug Conjugate (ADC) and Drug Delivery. He has published more than 20 papers/patents. He has been serving as a Guest Editor of Current Cancer Drug Targets since 2014.

Email: [email protected]

Top